Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants
Open Access
- 1 September 2017
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Stroke
- Vol. 48 (9), 2457-2463
- https://doi.org/10.1161/strokeaha.117.017981
Abstract
Background and Purpose—: In patients receiving direct oral anticoagulants (DOACs), emergency treatment like thrombolysis for acute ischemic stroke is complicated by insufficient availability of DOAC-specific coagulation tests. Conflicting recommendations have been published concerning the use of global coagulation assays for ruling out relevant DOAC-induced anticoagulation. Methods—: Four hundred eighty-one samples from 96 DOAC-treated patients were tested using prothrombin time (PT), activated partial thromboplastin time (aPTT) and thrombin time (TT), DOAC-specific assays (anti-Xa activity, diluted TT), and liquid chromatography–tandem mass spectrometry. Sensitivity and specificity of test results to identify DOAC concentrations <30 ng/mL were calculated. Receiver operating characteristic analyses were used to define reagent-specific cutoff values. Results—: Normal PT and aPTT provide insufficient specificity to safely identify DOAC concentrations 95% specificity and a specific TT cutoff enhanced sensitivity for dabigatran to 84%. For apixaban, no cutoffs could be established. Conclusions—: Even if highly DOAC-reactive reagents are used, normal results of global coagulation tests are not suited to guide emergency treatment: whereas normal PT and aPTT lack specificity to rule out DOAC-induced anticoagulation, the low sensitivity of normal TT excludes the majority of eligible patients from treatment. However, reagent-specific cutoffs for global coagulation tests ensure high specificity and optimize sensitivity for safe emergency decision making in rivaroxaban- and dabigatran-treated patients. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifiers: NCT02371044 and NCT02371070.This publication has 26 references indexed in Scilit:
- Recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 13–15 November 2016European Stroke Journal, 2017
- Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulantsCritical Care, 2017
- Coagulation Testing in Acute Ischemic Stroke Patients Taking Non–Vitamin K Antagonist Oral AnticoagulantsStroke, 2017
- Measuring non-vitamin K antagonist oral anticoagulant levels: When is it appropriate and which methods should be used?International Journal of Stroke, 2016
- UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional AssaysPLOS ONE, 2015
- Point-of-Care Testing of Coagulation in Patients Treated With Non–Vitamin K Antagonist Oral AnticoagulantsStroke, 2015
- Antidotes for Novel Oral AnticoagulantsArteriosclerosis, Thrombosis, and Vascular Biology, 2015
- National Trends in Ambulatory Oral Anticoagulant UseThe American Journal of Medicine, 2015
- The laboratory and the direct oral anticoagulantsBlood, 2013
- Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxabanClinical Research in Cardiology, 2013